

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **PW MEDTECH GROUP LIMITED**

**普华和顺集团公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

### **CONNECTED TRANSACTION ALLOTMENT RESULTS OF APPLICATION FOR SHARES IN THE IPO OF LEPU BIOPHARMA CO., LTD.**

Reference is made to the announcement (the “**Announcement**”) of PW Medtech Group Limited (the “**Company**”) dated 10 February 2022 in relation to the application for shares in the IPO of Lepu Biopharma (Stock Code: 2157). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Company has been allocated with 10,866,000 Lepu Biopharma Shares at the final offer price of HK\$7.13 each. The total amount paid by the Company in respect of the allocated Lepu Biopharma Shares is approximately HK\$78.3 million (including brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015%). There is no selling restriction on the allocated Lepu Biopharma Shares.

By order of the Board  
**PW Medtech Group Limited**  
**Yue’e Zhang**  
*Chairman*

Hong Kong, 22 February 2022

*As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue’e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.*